Wells Fargo & Company reiterated their outperform rating on shares of Aetna (NYSE:AET) in a research note released on Monday. The brokerage currently has a $208.00 price target on the stock, up from their prior price target of $200.00.
A number of other analysts have also recently commented on AET. Cantor Fitzgerald reaffirmed an overweight rating and issued a $175.00 price target (up from $150.00) on shares of Aetna in a research note on Wednesday, August 9th. Zacks Investment Research cut Aetna from a buy rating to a hold rating in a research note on Tuesday, October 3rd. Deutsche Bank increased their target price on Aetna from $157.00 to $163.00 and gave the stock a hold rating in a research note on Monday, August 7th. Citigroup increased their target price on Aetna from $183.00 to $197.00 and gave the stock a buy rating in a research note on Thursday, November 2nd. Finally, Jefferies Group increased their target price on Aetna from $165.00 to $185.00 and gave the stock a hold rating in a research note on Wednesday, November 1st. Eleven research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $174.14.
Shares of Aetna (NYSE AET) traded down $2.61 during mid-day trading on Monday, hitting $178.70. The stock had a trading volume of 23,978,400 shares, compared to its average volume of 2,550,395. The company has a current ratio of 0.53, a quick ratio of 0.53 and a debt-to-equity ratio of 0.52. The company has a market cap of $59,125.19, a PE ratio of 17.76, a PEG ratio of 1.65 and a beta of 0.61. Aetna has a one year low of $116.04 and a one year high of $192.37.
Aetna (NYSE:AET) last announced its quarterly earnings results on Tuesday, October 31st. The company reported $2.45 EPS for the quarter, beating analysts’ consensus estimates of $2.06 by $0.39. The company had revenue of $14.99 billion during the quarter, compared to analysts’ expectations of $15.12 billion. Aetna had a return on equity of 21.84% and a net margin of 2.93%. Aetna’s revenue was down 5.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.07 EPS. analysts anticipate that Aetna will post 9.78 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Thursday, January 11th will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.12%. Aetna’s dividend payout ratio is currently 37.04%.
In other news, President Karen S. Lynch sold 15,271 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $161.91, for a total transaction of $2,472,527.61. Following the completion of the transaction, the president now directly owns 64,261 shares of the company’s stock, valued at approximately $10,404,498.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Margaret M. Mccarthy sold 10,288 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $162.85, for a total transaction of $1,675,400.80. Following the transaction, the executive vice president now directly owns 33,563 shares of the company’s stock, valued at $5,465,734.55. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. State of Tennessee Treasury Department boosted its holdings in shares of Aetna by 26.3% in the 2nd quarter. State of Tennessee Treasury Department now owns 557,814 shares of the company’s stock valued at $84,692,000 after buying an additional 116,280 shares during the last quarter. Fayez Sarofim & Co. boosted its holdings in shares of Aetna by 82.8% in the 3rd quarter. Fayez Sarofim & Co. now owns 7,427 shares of the company’s stock valued at $1,181,000 after buying an additional 3,365 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Aetna by 4.2% in the 3rd quarter. Wells Fargo & Company MN now owns 1,365,596 shares of the company’s stock valued at $217,144,000 after buying an additional 54,928 shares during the last quarter. Banque Pictet & Cie SA acquired a new stake in shares of Aetna in the 2nd quarter valued at approximately $10,567,000. Finally, Pictet & Cie Europe SA acquired a new stake in shares of Aetna in the 2nd quarter valued at approximately $2,269,000. 88.03% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Aetna’s (AET) Outperform Rating Reaffirmed at Wells Fargo & Company” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/05/aetnas-aet-outperform-rating-reaffirmed-at-wells-fargo-company.html.
Aetna Company Profile
Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.
Receive News & Ratings for Aetna Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna Inc. and related companies with MarketBeat.com's FREE daily email newsletter.